1 / 7

Control

16. 3. 3. 12. CDH1. CDKN1A. 2. KLK11. 2. 8. 1. 1. 4. 0. 0. 0. Control. Trastuzumab. Pertuzumab. Combination. Control. Trastuzumab. Pertuzumab. Combination. Control. Trastuzumab. Pertuzumab. Combination. 1.5. 1.5. 1.0. 1.0. IL8. TGFBI. 0.5. 0.5. 0.0. 0.0.

kerem
Download Presentation

Control

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 16 3 3 12 CDH1 CDKN1A 2 KLK11 2 8 1 1 4 0 0 0 Control Trastuzumab Pertuzumab Combination Control Trastuzumab Pertuzumab Combination Control Trastuzumab Pertuzumab Combination 1.5 1.5 1.0 1.0 IL8 TGFBI 0.5 0.5 0.0 0.0 Control Trastuzumab Pertuzumab Combination Control Trastuzumab Pertuzumab Combination 3 2.0 3 1.5 2 PTPRR STC1 2 SERPINB5 1.0 1 1 0.5 0.0 0 0 Control Trastuzumab Pertuzumab Combination Control Trastuzumab Pertuzumab Combination Control Trastuzumab Pertuzumab Combination 1.5 3 MMP7 1.0 ENPP2 2 0.5 1 0 0 Control Trastuzumab Pertuzumab Combination Control Trastuzumab Pertuzumab Combination Supplementary Figure 1A

  2. 3 2 1 0 -1 -2 Illumina BeadChip R2 = 0.9694 p < 0.0001 -3 -2 -1 0 1 2 3 4 qRT-PCR Supplementary Figure 1B

  3. TrastuzumabPertuzumabCombined Supplementary Figure 2A

  4. TrastuzumabPertuzumabCombined Supplementary Figure 2B

  5. HER3-HER2 HER1-HER2 Homo- or Heterodimers Data from Ghosh et al. (2010) Cancer Research 71:1871-1882 Control.1 Control.1 Control.2 AP1510.3 AP1510.2 AP1510.3 Heregulin.1 Heregulin.2 Heregulin.3 TGFalpha.1 TGFalpha.2 TGFalpha.3 HER2-HER2 ControlTrastuzumabPertuzumabCombined DST, CDKN1A, CLIC6 JUN, JUP ControlTrastuzumabPertuzumabCombined JUN, SERPIN-A1/B5, MMP13, KRT-6A/16/7, ANXA8, PAK6 KRT5, ERBB3, CDH1, FOXO1 LCN2, KLK11 Both HER2 inhibitors AND combination CD9, KRT14 CD36, CD36, CASP1 NRG4 Pertuzumab alone AND combination PAK1 LAMA3 FOS, DUSP1, SNAI2 IL4R, CCL26, GADD45 Either HER2-inhibitor alone CAV2, JAG1 IL8, IL8 TGFBI, SPARC CDH6, CAV1, CXCL1 LAMC2, LAMC2 IL6, IL15 GSTA1, GSTA2 ESR1 CDH17 TFF2, TFF3 Trastuzumab alone AND combination Trastuzumab alone Pertuzumab alone Combination only Supplementary Figure 2C

  6. Heatmap from Ghosh et al. (2010) Cancer Research 71:1871-1882 Control.1 Control.1 Control.2 AP1510.3 AP1510.2 AP1510.3 Heregulin.1 Heregulin.2 Heregulin.3 TGFalpha.1 TGFalpha.2 TGFalpha.3 HER1-HER2 HER3-HER2 HER2-HER2 Homo- or Heterodimers ControlTrastuzumabPertuzumabCombined Supplementary Figure 2D

  7. SKOV3 (2.15) HOX486 (0.89) HOX516 (1.2) HOX424 (7.75) OV1002 (0.94) HOX493 (0.575) Supplementary Figure 3

More Related